Valuation : Polaris Group

Market Cap 8.86B 281M 241M 227M 207M 388M 26.55B 389M 2.69B 1.04B 13.6B 1.05B 1.03B 43.3B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 9.37B 297M 255M 240M 219M 410M 28.1B 412M 2.85B 1.1B 14.39B 1.12B 1.09B 45.83B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day-0.48%
1 week-8.04%
Current month-3.74%
1 month-8.04%
3 months-23.13%
6 months-66.34%
Current year-66.88%
1 week 10.2
Extreme 10.2
10.8
1 month 10.1
Extreme 10.1
13
Current year 10.1
Extreme 10.1
35.95
1 year 10.1
Extreme 10.1
39.15
3 years 10.1
Extreme 10.1
87.7
5 years 10.1
Extreme 10.1
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 2019-02-28
Chief Operating Officer - 2019-01-31
Chief Executive Officer - 2014-04-30
Director TitleAgeSince
Chairman 64 2014-11-23
Director/Board Member - 2020-02-24
Director/Board Member - 2020-01-02
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%-8.04%-73.07%-87.88% 281M
-1.16%-3.97%-2.91%+13.00% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
-0.96%-2.31%+15.75%+45.41% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.54%-1.05%+12.16%+29.80% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.91%+0.06%+57.26%+87.71% 27.53B
Weighted average by Cap. -0.95%+0.05%+88.78%+128.19%

Financials

2024 2025
Net sales 107M 3.39M 2.92M 2.74M 2.5M 4.68M 321M 4.7M 32.52M 12.57M 164M 12.74M 12.46M 523M 40.6M 1.29M 1.11M 1.04M 950K 1.78M 122M 1.78M 12.34M 4.77M 62.32M 4.83M 4.73M 199M
Net income -2.5B -79.32M -68.21M -64.16M -58.57M -110M -7.5B -110M -761M -294M -3.84B -298M -291M -12.24B -3.93B -124M -107M -101M -91.9M -172M -11.77B -172M -1.19B -461M -6.03B -467M -457M -19.2B
Net Debt 9.19M 291K 251K 236K 215K 402K 27.55M 404K 2.79M 1.08M 14.11M 1.09M 1.07M 44.94M 517M 16.38M 14.09M 13.25M 12.1M 22.62M 1.55B 22.7M 157M 60.73M 793M 61.52M 60.18M 2.53B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
26-09-06 NT$10.30 -0.48% 808,499
26-09-04 NT$10.35 +0.49% 825,107
26-09-03 NT$10.30 -2.83% 1,005,655
26-09-02 NT$10.60 -0.93% 548,603
26-09-01 NT$10.70 0.00% 1,501,621
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!